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ABSTRACT
Sphingosine-1-phosphate (S1P) is a bioactive lipid involved in cell signaling 
and, if released from cells, also plays a crucial role in regulating the trafficking of 
lympho-hematopoietic cells, including primitive hematopoietic stem/progenitor cells 
(HSPCs). It has been demonstrated that S1P chemoattracts HSPCs, and its level in 
peripheral blood creates a gradient directing egress of these cells during mobilization. 
In this paper we analyzed hematopoiesis in mice deficient in sphingosine kinase 2 
(Sphk2-KO mice) and studied the effect of this mutation on plasma S1P levels. We 
found that Sphk2-KO mice have normal hematopoiesis, and, in contrast to Sphk1-
KO mice, the circulating S1P level is highly elevated in these animals and correlates 
with the fact that HSPCs in Sphk2-KO animals, also in contrast to Sphk1-KO animals, 
show enhanced mobilization. These results were recapitulated in wild type (WT) 
animals employing an Sphk2 inhibitor. We also administered an inhibitor of the S1P-
degrading enzyme S1P lyase, known as tetrahydroxybutylimidazole (THI), to WT 
mice and observed that this resulted in an increase in S1P level in PB and enhanced 
mobilization of HSPCs. In sum, our results support a crucial role for S1P gradients in 
blood plasma in the mobilization process and indicate that small-molecule inhibitors 
of Sphk2 and Sgpl1 could be employed as mobilization-facilitating compounds. At 
the same time, further studies are needed to explain the unexpected effect of Sphk2 
inhibition on increasing S1P levels in plasma.
INTRODUCTION
Evidence has accumulated that the bioactive 
lipid sphingosine-1-phosphate (S1P) is an important 
chemoattractant for lymphocytes [1, 2] and, together 
with ceramide-1-phosphate (C1P), plays a pivotal role 
in the trafficking of hematopoietic stem/progenitor 
cells (HSPCs) [2, 3]. S1P has been reported to play a 
role both in mobilization of HSPCs from bone marrow 
(BM) into peripheral blood (PB) [4–6] and in the reverse 
phenomenon of homing to BM of cells circulating in PB 
[7]. S1P is highly expressed in tissue fluids, such as blood 
and lymph, and in PB its most important sources are red 
blood cells, albumin, and apoM bound to high-density 
lipoproteins (HDL) [8]. The high concentration of S1P in 
PB creates an important chemotactic gradient across the 
endothelium between BM and PB [2].
As a bioactive lipid and a phosphorylated product 
of sphingosine, S1P is an important intracellular second 
messenger and, if released from the cells, is a ligand 
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for five different G protein-coupled S1P receptors 
(S1P1-5) [2, 9]. Of these receptors, S1P receptor type 1 
(S1P1) and (as recently demonstrated) S1P3 [2, 10–12] 
play an important role in the trafficking of lympho/
hematopoietic cells. An important source of sphingosine is 
ceramide, and sphingosine is derived from ceramides in a 
ceramidase-dependent manner. The process of sphingosine 
phosphorylation to produce S1P is governed by 
sphingosine kinases. Two forms of sphingosine kinase —
type 1 (Sphk1) and type 2 (Sphk2)—have been described 
[2, 13, 14]. Sphk1 is found in the cytosol of eukaryotic 
cells and shifts to the plasma membrane upon activation, 
while Sphk2 is localized to the cell nucleus [15]. As 
previously demonstrated, mice with Sphk1 knockout are 
poor HSPC mobilizers [5] and have impaired homing of 
HSPCs after transplantation [16].
On the one hand, S1P can be inactivated by 
dephosphorylation with sphingosine phosphate 
lyase (Sgpl1) [17]. Inhibition of Sgpl1 with 
tetrahydroxybutylimidazole (THI), which is a small-
molecule inhibitor of this enzyme, results in an increase 
in S1P levels in PB and leads to release of c-kit+ stem 
cells from BM in a mouse model of acute myocardium 
infarction [18]. On the other hand, Sgpl1 inhibition by THI 
has been related to its immunosuppressive role as a result 
of retention of lymphocytes in lymphoid organs, which 
results in lymphopenia [19].
Recently published results suggest a crucial role of 
the S1P level in PB in directing egress of HSPCs from 
BM into PB [20, 21]. To better address this question we 
performed mobilization studies in Sphk2-KO mice and 
WT mice exposed to inhibitors of Sphk2 and Sgpl1 to 
modulate the level of S1P in PB.
We show what is counterintuitive, that is, the S1P 
level in Sphk2-KO mice and wild type (WT) mice exposed 
to a small-molecule Sphk2 inhibitor is elevated relative to 
control animals and Sphk1-KO animals. The S1P plasma 
level was also increased in THI-treated animals. Moreover, 
our mobilization experiments lend further support to there 
being a crucial role of the S1P blood level in egress of 
HSPCs from BM into PB, as enhanced mobilization in 
Sphk2-deficient mice and WT mice exposed to Sphk2 
and Sgpl1 inhibitors was correlated with an increased S1P 
plasma level but not with significant changes in the level 
of CXCL12 (stromal-derived factor 1; SDF-1).
RESULTS
Sphingosine kinase 2-deficient (Sphk2-KO) mice 
show enhanced mobilization
It has been reported that the mobilization of HSPCs 
is impaired in sphingosine kinase 1-deficient (Sphk1-KO) 
mice, due to a low plasma level of S1P [5, 22]. Since 
Sphk2 is another enzyme involved in S1P synthesis, we 
became interested in whether a similar effect occurs in 
Sphk2-KO animals. However, to our surprise, as shown 
in Figure 1, we found that Sphk2-KO show enhanced 
mobilization in response to a short (3-day) G-CSF-, a long 
(6-day) G-CSF-, or Plerixafor-induced mobilization. 
Supplementary Figure 1 shows that the Sphk2-
KO mice employed in our studies have normal PB 
cell counts (Supplementary Figure 1A), red blood cell 
parameters (Supplementary Figure 1B), numbers of bone 
marrow-residing HSPCs (Supplementary Figure 1C), and 
clonogenic progenitors (Supplementary Figure 1D) under 
steady-state conditions compared with WT animals.
Changes in S1P and CXCL12 level in Sphk1-KO 
and Sphk2-KO mice
Since the mobilization of HSPCs from BM into 
PB correlates with the plasma level of S1P, we measured 
the S1P level in WT, Sphk1-KO and Sphk2-KO animals. 
Figure 2 shows that, in contrast to Sphk1-KO mice, the 
plasma level of S1P is significantly elevated in Sphk2-KO 
mice. Thus, the increase in S1P in the PB of Sphk2-mutant 
animals suggests the mobilization-promoting gradient for 
HSPCs. However, a molecular explanation of the increase 
in S1P is not clear at this time and requires further study. 
The S1P plasma level was also increased as expected in 
THI-treated Sphk1-KO mice. Interestingly Sphk2-KO 
mice, in contrast to Sphk1-KO and WT animals, also had 
elevated levels of C1P in PB (Supplementary Figure 2), 
which indicates that changes in S1P level in PB in Sphk2-
KO mice are echoed by changes in the level of another 
chemotactic factor for HSPCs, C1P [2, 23].
We also evaluated CXCL12 levels in conditioned 
media harvested from BM supernatants (Figure 2B) and 
PB plasma (Figure 2C) harvested from WT, Sphk1-KO, 
and Sphk2-KO mice mobilized for 6 days with G-CSF 
(Figure 2B). While there were no major changes in 
CXCL12 levels in the conditioned media and plasma of 
G-CSF-mobilized animals, the baseline CXCL12 level 
was enhanced in the plasma of Sphk1-KO mice. Of note, 
this increase in CXCL12 level in PB plasma reached 1.5 
ng/ml, which is still a very low concentration that, as we 
previously demonstrated, is not alone sufficient to promote 
migration of HSPCs [7, 20].
Inhibition of S1P lyase (Sgpl1) by 
tetrahydroxybutylimidazole (THI) enhances the 
S1P level in PB and enhances mobilization in WT 
animals
Since Sgpl1 degrades S1P, we became interested 
in whether inhibition of this enzyme would increase 
mobilization of HSPCs in WT animals. We found that 
inhibition of Sgpl1 did increase the S1P level in PB in 
both WT [19, 20, 25] and Sphk1-KO animals (Figure 2A). 
This increase in plasma S1P level was correlated with 
enhanced mobilization in WT mice exposed to the Sgpl1 
Oncotarget65590www.impactjournals.com/oncotarget
inhibitor THI. To support this Figure 3 shows enhanced 
mobilization of HSPCs in WT animals pretreated with THI 
in response to G-CSF and Plerixafor administration.
Inhibition of Sphk2 by small-molecule inhibitor 
of SLM6041434 enhances the S1P level in PB 
and enhances mobilization in WT animals
Moreover, corroborating our results shown in Figure 
2A, it has been recently reported that the S1P level is 
elevated in blood of WT mice exposed to a small-molecule 
inhibitor of Sphk2, SLM6041434 [24]. Therefore, to 
investigate whether WT mice exposed to SLM6041434 
better mobilize HSPCs, we performed mobilization studies 
in these animals. Figure 4 shows that WT mice exposed 
to SLM6041434 better mobilized HSPCs in response to 
G-CSF and Plerixafor than control animals not exposed to 
this Sphk2 inhibitor.
In comparison with WT animals, Sphk2-KO 
mice show defective BM engraftment of HSPCs
In our previous work we demonstrated that 
S1P enhances CXCL12-mediated homing and even 
compensates in case of any deficiency in homing to BM 
of HSPCs infused into PB [26]. Based on our current 
observation that the S1P plasma level is high in Sphk2-KO 
animals, we asked whether this increase prevents homing 
to BM of HSPCs. To address this question we performed 
WT HSPC transplants in WT and Sphk2-KO animals.
We found that Sphk2-KO mice transplanted with 
BMMNCs labeled with green immunofluorescence 
protein (GFP) showed impaired homing of GFP+ BM 
cells compared with WT mice 24 hours later (Figure 
5A). Moreover, 12 days after transplantation Sphk2-
KO animals transplanted with GFP+ BMMNCs had 
lower numbers of clonogenic CFU-GM colonies in BM 
Figure 1: Sphk2-KO mice show enhanced mobilization with G-CSF and Plerixafor. Mononuclear cells were isolated from 
WT and SphK2-KO mice after 3 days (Panel A) or 6 days (Panel B) of G-CSF mobilization (100 μg/kg per day, subcutaneously) or after 
Plerixafor-induced mobilization (5 mg/kg, intraperitoneal injection, Panel C). The numbers of WBCs, SKL (Sca-1+ c-kit+ Lin−) cells, HSCs 
(Sca-1+ CD45+ Lin−), and CFU-GM clonogenic progenitors were evaluated from PB. Results from two separate experiments are pooled 
together. *P ≤ 0.05.
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and lower numbers of CFU-S colonies than control 
WT animals (Figure 5B). Finally, Sphk2-KO animals 
transplanted with WT BMMNCs showed delayed recovery 
of neutrophil and platelet counts compared with control 
mice (Figure 6).
DISCUSSION
The seminal observation of this report is that Sphk2-
null mice and mice exposed to Sphk2 and Sgpl1 inhibitors 
have elevated S1P levels in PB and show enhanced 
Figure 2: Measurements of S1P and CXCL12 levels. Panel (A) Steady-state S1P plasma level in WT, Sphk1-KO, Sphk2-KO, and 
Sphk1-KO mice exposed to THI. Panel (B) CXCL12 concentration in conditioned media from BM after 6 days of G-CSF mobilization in 
Sphk1-KO and Sphk2-KO animals. Panel (C) Left: the plasma level of CXCL12 in Sphk1-KO and Sphk2-KO animals under steady-state 
conditions. Right: the plasma level of CXCL12 in Sphk1-KO and Sphk2-KO animals mobilized for 6 days with G-CSF. Results from two 
separate experiments are pooled together.  
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Figure 3: Impact of an S1P lyase (Sgpl1) inhibitor on the mobilization of HSPCs. WT mice received mobilizing agents and 
tetrahydroxybutylimidazole (THI) administered ad libitum in water or vehicle. Mononuclear cells were isolated after 3 days of G-CSF- 
(Panel A) or Plerixafor-induced mobilization (Panel B). The numbers of WBCs, SKL (Sca-1+ c-kit+ Lin−) cells, HSCs (Sca-1+ CD45+ Lin−), 
and CFU-GM clonogenic progenitors were evaluated in PB. Results from two separate experiments are pooled together. *P ≤ 0.05.
Figure 4: Impact of an Sphk2 inhibitor on the mobilization of HSPCs. WT mice received mobilizing agents and SLM6041434 
compound (or instead of SLM6041434 compound, control mice received vehicle). Mononuclear cells were isolated after 3 days of G-CSF- 
(Panel A) or Plerixafor-induced mobilization (Panel B). The numbers of WBCs, Sca-1+ c-kit+ Lin− cells (SKL cells), HSCs (Sca-1+ CD45+ 
Lin−), and CFU-GM clonogenic progenitors were evaluated in PB. Results from two separate experiments are pooled together. *P ≤ 0.05.
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mobilization of HSPCs. Thus, our results support the 
conclusion that S1P is a major PB chemoattractant for 
HSPCs [2, 4, 5, 16, 20]. We also demonstrate that in the 
reverse process of homing of HSPCs from PB into BM, an 
elevated S1P level in PB, as seen in Sphk2-KO animals, 
may impair hematopoietic cell homing and engraftment. 
Overall, our results provide further support for the 
presence of a “tug of war” between BM and PB mediated 
by an S1P gradient that affects trafficking of HSPCs [27].
S1P has been proposed to play a role in trafficking 
of lymphocytes [1, 2], and more recently this trafficking 
has been found to include egress of hematopoietic 
progenitor cells form BM into PB [4–6]. Specifically, 
our group and others have demonstrated the pivotal 
role of S1P in egress of both hematopoietic stem cells 
and hematopoietic progenitors from BM into PB in 
the process of pharmacological mobilization induced 
by G-CSF or Plerixafor [5, 20]. We also proposed 
the concept that the S1P level is already very high in 
circulating PB under steady-state conditions, which 
supports the notion that HSPCs are actively retained in 
the BM microenvironment by the CXCL12–CXCR4 and 
VCAM-1–VLA4 axes to prevent their egress into PB in 
response to an S1P gradient [21, 28]. The S1P level in PB 
may also increase during mobilization in response to the 
release of this chemoattractant from red blood cells and 
platelets in response to activation of the complement and 
coagulation cascades [2, 20, 21]. Both of these cascades 
are crucial in induction of mobilization processes in 
response to pharmacology, inflammation, stress, or tissue 
injury [6, 29–33].
Interestingly an increase in S1P level alone in 
response to red blood cell hemolysis (for example, 
induced by administration of phenylhydrazine (PHZ), 
when neither complement nor coagulation cascades are 
activated) does not significantly induce egress of HSPCs 
Figure 5: Defects in homing and short-term engraftment of HSPCs in Sphk2-KO mice. Panel (A) Lethally irradiated 
mice (six mice per group) were transplanted with 7 × 106 bone marrow mononuclear cells (BMMNCs) from B6-GFP+ mice. Twenty-four 
hours after transplantation, femoral BMMNCs were harvested, the number of GFP+ cells was evaluated by FACS (Panel A, left), and 
the clonogenic CFU-GM progenitors were enumerated in an in vitro colony assay (Panel A, right). No colonies were formed in lethally 
irradiated and non-transplanted mice (irradiation control). Panel (B) Lethally irradiated mice (six per group) were transplanted with 2.5 × 105 
BMMNCs from WT mice. Twelve days after transplantation, femoral BMMNCs were harvested to evaluate the number of CFU-GM 
colonies in clonogeneic assays (Panel B, left), and the spleens were removed to enumerate the number of CFU-S colonies (Panel B, right). 
The data represent the combined results from two independent experiments for each panel. *p < 0.005.
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into the circulation [21]. As reported, the doubling of 
S1P level in PB from damaged erythrocytes in response 
to PHZ-induced hemolysis only marginally increased the 
number of HSPCs circulating in PB. However, if mice are 
exposed to PHZ together with the CXCR4 blocking agent, 
Plerixafor, a robust synergistic increase in the number of 
mobilized HSPCs occurred [21]. This finding supports 
the concept that HSPCs first have to be released from 
BM niches by blocking the CXCL12–CXCR4 retention 
signal in order to respond to the S1P gradient between 
BM and PB. This is why induction of a proteolytic [34] 
and lipolytic [35] microenvironment in BM initiated by 
activation of the complement cascade[7, 8] is crucial to 
attenuating the biological function of the retention axes 
for HSPCs in BM and facilitates their egress into PB in 
response to an S1P gradient [7, 8, 34, 35].
S1P is synthesized by phosphorylation of 
sphingosine by the kinases Sphk1 and Sphk2 and is 
degraded by Sgpl1 or S1P phosphatase or is extruded 
by S1P transporters, such as sphingolipid transporter 2 
(Spns2) [2, 13, 14, 17, 36]. Mice that are deficient in 
both Sphk1 and Sphk2 die in utero with no detectable 
S1P, which suggests an important role for S1P in 
development [9]. However, single-knockout mice are 
viable. Interestingly, while Sphk1-KO mice display a 
decrease by ~50% of the S1P level circulating in PB 
[37], mice with Sphk2 deficiency have a somewhat 
unexpected 2–4-fold increase in S1P level in PB plasma 
and whole blood [24, 38]. It has already been reported 
that Sphk1-KO mice are poor mobilizers of HSPCs 
[5], which nicely correlates with the low level of blood 
plasma S1P in these animals [37]. Based on the fact that 
Sphk2-KO mice have elevated levels of S1P in PB, we 
performed mobilization studies in these animals and 
demonstrated that, as expected, they show enhanced 
mobilization after 3-day or 6-day administration of 
Figure 6: Defects in engraftment of HSPCs in Sphk2-KO mice. Lethally irradiated WT and Sphk2-KO mice were transplanted 
with 2 × 105 BMMNCs from WT cells. White blood cells (Panel A) and platelets (Panel B) were counted before irradiation and at intervals 
5, 7, 11, 16, 21, and 28 days after irradiation. The data represent the combined results from two independent experiments for each panel. 
*p < 0.005.
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G-CSF and after mobilization by employing the CXCR4 
receptor antagonist Plerixafor.
This increase in S1P level in peripheral blood 
in Sphk2-KO mice correlating with their enhanced 
mobilization state was reproduced using a nontoxic dose 
of the Sphk2 inhibitor SLM6041434. In our hands, WT 
mice exposed to this compound better mobilized HSPCs 
after either G-CSF or Plerixafor administration, and we 
confirmed that this correlated with an increase in S1P 
level in PB. We obtained additional support for the pivotal 
role of an increase in S1P level in circulating blood in the 
egress of HSPCs from BM by employing the commercially 
available Sgpl1 inhibitor tetrahydroxybutylimidazole 
(THI) [18, 19, 25]. WT mice exposed to this compound 
again turned out to better mobilize HSPCs than control 
animals not exposed to THI. This observation supports our 
recent results performed in mice after experimental acute 
myocardium infarction (AMI) in which administration of 
THI led to an increase in S1P level in PB and mobilization 
of c-kit+ stem cells from BM [18]. This enhanced 
mobilization of stem cells resulted in an increase in 
angiogenesis, improved recovery of cardiac functional 
parameters, and reduction in scar size [18].
The increased baseline level of S1P in Sphk2-KO 
mice is intriguing. As reported recently, mass-labeled S1P 
is cleared more slowly in these mutant animals, which 
suggests that Sphk2 deficiency results also in decreased 
clearance of circulating S1P and strongly suggests that this 
enzyme may have additional yet-unrecognized functions 
independent of the intracellular synthesis of S1P [24]. 
Several explanations for this phenomenon have been 
proposed [24], for example, a compensatory increase in 
Sphk1 activity or a so-far-uncharacterized S1P-degrading 
capacity as a lyase or phosphatase. However none of these 
explanations is conclusive, and this phenomenon requires 
further study.
A striking aspect of S1P biology is its 
compartmentalization between tissues and circulating 
fluids [24, 39, 40]. Specifically, S1P levels are, as 
mentioned above, significantly higher in PB and lymph 
than in tissues, for example, in the BM microenvironment 
[8]. However, as we previously demonstrated, the 
S1P level is upregulated in BM after conditioning for 
hematopoietic transplant by radio- or chemotherapy [7]. 
This effect supports the presence of a dynamic tug of war 
between the S1P gradient (between PB and BM) and the 
retention axes. The important role of S1P in homing of 
HSPCs, which functionally supports the CXCL12–CXCR4 
homing axis, has been demonstrated after transplantation 
of CXCR4-deficient HSPCs into Sphk1-KO animals [16]. 
In the current paper we support this tug-of-war concept 
between the S1P gradient between BM and PB and the 
retention axes and demonstrate that a high level of S1P 
in PB, as seen in Sphk2-KO mice, impairs both homing 
and short-term engraftment of HSPCs in lethally irradiated 
WT mice.
Since a role for S1P has been proposed in the 
trafficking of malignant hematopoietic cells, targeting 
the S1P axis may also become an important part of anti-
leukemic therapy [2]. The mechanism of Sphk2 inhibitors 
in leukemia is mainly based on increasing autophagic 
death, as seen for example in T cell-acute lymphocytic 
leukemia [41, 42], or a decrease in cell proliferation and 
induction of apoptosis in multiple myeloma cells [43]. Our 
findings reported in this work show that there are most 
likely clear differences in the Sphk2 requirement between 
normal and malignant hematopoietic cells, as Sphk2 
deficiency does not affect normal hematopoiesis in Sphk2-
KO mice, and we did not observe any negative effects of 
an Sphk2 inhibitor on clonogenic proliferation of normal 
HSPCs in the in vitro toxicity studies performed.
In conclusion, our novel results support the 
overall concept that the S1P level in PB is a major 
chemoattractant for BM-residing HSPCs and the presence 
of a tug of war between BM and PB due, in part, to this 
bioactive sphingolipid. Thus, changes in S1P gradient 
direct mobilization of HSPCs and may affect BM homing 
of these cells after transplantation. Moreover, drugs that 
inhibit Sphk2 activity (e.g., SLM6041434) or inhibit 
Sgpl1 (e.g., THI) could increase our armamentarium of 
available HSPC-mobilizing drugs. Since it has also been 
demonstrated that another bioactive sphingolipid, C1P, 
also directs trafficking of HSPCs, and its level is elevated 
in SphK2-KO animals, further studies are needed to 




In our experiments we employed pathogen-free, 6- to 
8-week-old C57BL/6J (WT), B6N.129S6-Sphk1tm1Rlp/J 
(Sphk1-KO) and B6N.129S6-Sphk2tm1Rlp/J (Sphk2-
KO) female mice established by Rick Proia [13, 16] and 
purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA) at least 2 weeks before the experiments. Animal 
studies were approved by the Animal Care and Use 
Committee of the University of Louisville (Louisville, 
KY, USA).
Drug administration
For Sphk2 inhibition, mice were injected i.p. with 
5 mg/kg SLM6031434 or an equal volume of vehicle 
(2% solution of hydroxypropyl-β-cyclodextrin; Cargill 
Cavitron 82004; Cargill Inc., Cedar Rapids, IA). To 
inhibit S1P lyase, mice received vehicle or 25 mg/L 
tetrahydroxybutylimidazole THI (Sigma-Aldrich, St. 
Louis, MO) administered ad libitum in water containing 
5% dextrose (to improve palatability). THI is a Food and 
Drug Administration-approved caramel food coloring 
Oncotarget65596www.impactjournals.com/oncotarget
additive shown to inhibit S1P lyase when administered 
orally to mice [19, 25].
Murine bone marrow-derived mononuclear cells 
Bone marrow-derived mononuclear cells 
(BMMNCs) were obtained by flushing femurs and tibias 
of pathogen-free experimental mice. Cells were lysed with 
BD Pharm Lyse buffer (BD Biosciences, San Jose, CA, 
USA) to remove red blood cells, washed, and resuspended 
in appropriate media for further analysis [35, 44].
Mobilization
Experimental mice were injected subcutaneously 
(s.c.) with 100 μg/kg G-CSF (Amgen, Thousand Oaks, 
CA, USA) daily for 3 (short mobilization) or 6 (long 
mobilization) days and one dose at 5 mg/kg (i.p.) of 
Plerixafor (AMD3100) (Sigma-Aldrich). At 6 h after 
the last G-CSF administration or at 1 h after Plerixafor 
injection mice were bled from the retro-orbital plexus for 
hematology analysis, and PB was obtained from the vena 
cava with a 25-gauge needle and 1-ml syringe containing 
50 μl of 100 mM ethylenediaminetetraacetic acid (EDTA; 
Quality Biological Inc., Gaithersburg, MD, USA). 
Mononuclear cells (MNCs) were obtained by hypotonic 
lysis of RBCs in BD Pharm Lyse buffer [35, 44].
Fluorescence-activated cell sorting (FACS) 
analysis 
The following monoclonal antibodies were 
used to perform staining of Lin−/Sca-1+/c-Kit+ (SKL) 
cells and Lin−/Sca-1+/CD45+ hematopoietic stem cells 
(HSCs): FITC–anti-CD117 (also known as c-Kit, clone 
2B8; BioLegend, San Diego, CA, USA) and PE–Cy5–
anti-mouse Ly-6 A/E (also known as Sca-1, clone D7; 
eBioscience, San Diego, CA, USA). All anti-mouse 
lineage marker [5] antibodies, including anti-CD45R/
B220 (clone RA3-6B2), anti-Ter-119 (clone TER-119), 
anti-CD11b (clone M1/70), anti-T cell receptor β (clone 
H57-597), anti-Gr-1 (clone RB6-8C5), anti-TCRγδ (clone 
GL3), and anti-CD45 (clone 30-F11), were purchased 
from BD Biosciences and conjugated with PE as described 
[35, 44]. Staining was performed in RPMI 1640 medium 
containing 2% FBS. All monoclonal antibodies (mAbs) 
were added at saturating concentrations, and the cells were 
incubated for 30 min on ice, washed twice, and analyzed 
with an LSR II flow cytometer (BD Biosciences).
Evaluation of HSPC mobilization 
For evaluation of circulating colony-forming unit-
granulocyte/macrophage (CFU-GM) and SKL cells, the 
following formulas were used: (number of white blood 
cells [WBCs]) x number of CFU-GM colonies)/number 
of WBCs plated = number of CFU-GM per μl of PB; and 
(number of WBCs x number of SKL cells)/number of 
gated WBCs = number of SKL cells per μl of PB [35, 44].
PB parameter counts
To obtain leukocyte and RBC counts, 50 μl of PB 
was taken from the retro-orbital plexus of the mice and 
collected in microvette EDTA-coated tubes (Sarstedt Inc., 
Newton, NC, USA), and samples were analyzed within 2 h 
of collection on a HemaVet 950 analyzer (Drew Scientific 
Inc., Waterbury, CT, USA) [35, 44, 45].
Clonogenic in vitro assay
RBCs from PB or BM were lysed with BD Pharm 
Lyse buffer. Nucleated cells were subsequently washed, 
counted, and resuspended in human methylcellulose 
base medium provided by the manufacturer (R&D 
Systems, Minneapolis, MN, USA). To evaluate the 
number of clonogenic progenitor cells, BMMNCs were 
supplemented with erythropoietin (5 U/ml; Stemcell 
Technologies, Vancouver, BC, Canada) plus stem cell 
factor (SCF; 5 ng/ml; R&D Systems) and resuspended 
in methylcellulose base medium (for determining the 
number of burst-forming units-erythroid; BFU-E)(R&D 
Systems). For determining the number of  megakaryocytic 
progenitors (CFU-Meg) BM-MNC were supplemented 
with thrombopoietin (100 ng/ml; Gibco Thermo Fisher 
Scientific, Waltham, MA, USA) plus mIL-3 (10 ng/ml; 
ProSpec-Tany Technogene Ltd., East Brunswick, NJ, 
USA), and resuspended in plasma clots. For determining 
number of granulocyte/monocytic colonies (CFU-GM) 
BM-MNC were supplemented with 25 ng/ml recombinant 
murine granulocyte macrophage colony-stimulating factor 
(mGM-CSF; Millipore, Billerica, MA, USA) and 10 ng/ml 
recombinant murine interleukin 3 (mIL-3; Millipore) and 
cultured in in methylcellulose base medium. Cultures were 
incubated for 7 to 14 days (37°C, 95% humidity, and 5% 
CO2), at which time they were counted under an inverted 
microscope (Olympus CK40; Olympus, Shinjuku, Tokyo, 
Japan) [16, 44, 45].
Quantitation of S1P and C1P levels
PB samples were obtained from the retro-orbital 
plexus of the mice into tubes containing 1:5 ratio of 
EDTA:CTAD. Plasma was isolated by centrifuging 
whole blood for 10 min at 700 g. Supernatant was then 
removed and centrifuged at 10,000 g for 10 min to 
remove platelets, and the supernatant was then used for 
lipid measurements. Lipids were extracted from plasma, 
supernatant using acidified organic solvents, as previously 
described [46, 47]. An analysis of S1P and C1P was 
carried out using a Shimadzu UFLC coupled with an AB 
Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole 
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mass spectrometer in multiple reaction monitoring mode 
as previously described [47]. The mobile phase consisted 
of 75/25 of methanol/water with formic acid (0.5%) 
and 5mM ammonium formate (0.1%) as solvent A and 
99/1of methanol/water with formic acid (0.5%) and 5mM 
ammonium formate (0.1%) as solvent B. The column was 
equilibrated back to the initial conditions in 3min. The 
flow rate was 0.5mL/min with a column temperature of 
60°C. The sample injection volume was 10 μL. The mass 
spectrometer was operated in the positive electrospray 
ionization mode with optimal ion source settings 
determined by synthetic standards with a declustering 
potential of 46V, entrance potential of 10V, collision 
energy of 19V, collision cell exit potential of 14V, curtain 
gas of 30psi, ion spray voltage of 5,500V, ion source gas1/
gas2 of 40psi, and temperature of 550°C. for S1P, total 
S1P (DH-S1P and S1P) is reported. For C1P, total C1P 
which is the sum of all C1P species (C2-C1P, C12-C1P, 
C-14 C1P, C16-C1P, DH-16 –C1P, C18-C1P, C18-1-C1P, 
C20-C1P, C22-C1P, C24-C1P, C24-C1P, C24-1-C1P, C26-
C1P and C26-1-C1P) is reported.
CXCL12 assessment following G-CSF and 
Plerixafor therapy
6-8-week-old sphingosine kinase 1 and 2 KO 
mice as well as appropriate age- and sex-matched C57/
Bl6 WT control mice were used for these studies. Mice 
were mobilized by subcutaneous injection of 100 μg/kg 
human G-CSF (Amgen, Thousand Oaks, CA) daily for 6 
days and a single intraperitoneal injection of Plerixafor 
5 mg/kg (Sigma, St. Louis, MO) on the sixth day. Six 
hours after the last G-CSF injection/2 h post Plerixafor 
injection, peripheral blood (PB) [47] was obtained from 
the vena cava (with a 25-gauge needle and 1-mL syringe 
containing CTAD + EDTA). Plasma was obtained using 
centrifugation of PB samples at 700g for 10 minutes. 
Bone marrow (BM) supernatant was isolated from flushed 
tibia and femur in identical volume (500 µl) of ice-cold 
PBS. Supernatant was isolated following centrifugation at 
700g for 10 minutes. CXCL12 ELISA (DY460 kit) was 
performed in duplicate on plasma and BM supernatant 
samples using manufacturer protocol (R&D Systems, 
Minneapolis, MN, USA) [35].
Short-term homing experiments 
Lethally irradiated experimental mice (γ-irradiation 
at 1000 cGy) 24 h after irradiation were transplanted 
(by tail vein injection) with 7 × 106 BM cells from B6-
GFP mice. At 24 h after transplant, BM cells from the 
femurs were isolated via Ficoll-Paque and divided, and 
30% of the cells were analyzed by FACS. The rest of the 
cells were plated in serum-free methylcellulose cultures 
and stimulated to grow CFU-GM colonies with mGM-
CSF (25 ng/ml) and mIL-3 (10 ng/ml). After 7 days 
of incubation (37°C, 95 % humidity, and 5 % CO2), 
the number of colonies was scored under an inverted 
microscope [16, 44, 45].
Evaluation of engraftment 
For short-term engraftment experiments, 
experimental mice were irradiated with 1000 cGy of 
γ-irradiation. After 24 h, mice were transplanted by tail 
vein injection with 2.5 × 105 BM cells from WT mice, 
and the femora of the transplanted mice were flushed 
with PBS on day 12 post-transplant. After purification 
via Ficoll-Paque, BM cells were plated in serum-free 
methylcellulose cultures and stimulated to grow CFU-
GM colonies with mGM-CSF (25 ng/ml) and IL-3 
(10 ng/ml). After 7 days of incubation (37°C, 95 % 
humidity, and 5 % CO2) the number of colonies was 
scored under an inverted microscope. Spleens were also 
removed, fixed in Telesyniczky’s solution for CFU-S 
assays, and the colonies on the surface of the spleen 
counted [16, 44, 45].
Recovery of leukocytes and platelets 
Experimental mice were lethally irradiated, and after 
24 h the animals were transplanted by tail vein injection 
with 2 × 105 BM cells from WT mice. Transplanted mice 
were bled at various intervals from the retro-orbital plexus 
to obtain samples for white blood cell and platelet counts. 
Fifty microliters of PB was taken from the retro-orbital 
plexus of the mice into EDTA-coated Microvette tubes 
(Sarstedt Inc., Newton, NC, USA) and run within 2 h 
of collection on a HemaVet 950FS hematology analyzer 
(Drew Scientific Inc., Oxford, CT, USA) [16, 44, 45].
Statistical analysis
All results are presented as mean ± SD. Statistical 
analysis of the data was done using Student’s t-test for 
unpaired samples (Excel, Microsoft Corp., Redmond,WA, 
USA) with a value of p ≤ 0.05 considered significant.
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